In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

Nature Medicine

Volumn 20, Issue 3, 2014, Pages 313-318

  Atreya, Raja ^a   Neumann, Helmut ^a   Neufert, Clemens ^a   Waldner, Maximilian J ^a   Billmeier, Ulrike ^a   Zopf, Yurdagül ^a   Willma, Marcus ^a   App, Christine ^a   Münster, Tino ^a   Kessler, Hermann ^a   Maas, Stefanie ^a   Gebhardt, Bernd ^a   Heimke Brinck, Ralph ^b   Reuter, Eva ^b   Dörje, Frank ^b   Rau, Tilman T ^a   Uter, Wolfgang ^a   Wang, Thomas D ^c   Kiesslich, Ralf ^d   Vieth, Michael ^e   Hannappel, Ewald ^a   Neurath, Markus F ^a   more..

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF MICHIGAN   (United States)

^d St Mary's Hospital   (Germany)

^e INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CROHN DISEASE; EX VIVO STUDY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; HUMAN; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MALE; MOLECULAR IMAGING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INFLAMMATION; INTESTINAL MUCOSA; INTESTINES; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896117860     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3462     Document Type: Article

References (40)

1. Strober, W., Fuss, I. & Mannon, P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117, 514-521 (2007
2. Danese, S. New therapies for inflammatory bowel disease: From the bench to the bedside. Gut 61, 918-932 (2012
3. Peyrin-Biroulet, L., Loftus, E.V. Jr., Colombel, J.F. & Sandborn, W.J. The natural history of adult Crohn's disease in population-based cohorts. Am. J. Gastroenterol. 105, 289-297 (2010
4. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6, 583-588 (2000
5. Wajant, H., Pfizenmaier, K. & Scheurich, P. Tumor necrosis factor signaling. Cell Death Differ. 10, 45-65 (2003
6. Colombel, J.F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010
7. Evans, A.T. & Lee, S.D. A review and expert opinion of the use of certolizumab for Crohn's disease. Expert Opin. Biol. Ther. 12, 363-370 (2012
8. Hanauer, S.B. et al. Human anti-Tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 130, 323-333, quiz 591 (2006
9. Colombel, J.F. et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15, 1308-1319 (2009
10. Vermeire, S., Van Assche, G. & Rutgeerts, P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm. Bowel Dis. 10, 661-665 (2004
11. Hlavaty, T. et al. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm. Bowel Dis. 13, 372-379 (2007
12. Kendall, C. et al. Raman spectroscopy, a potential tool for the objective identification and classification of neoplasia in Barrett's oesophagus. J. Pathol. 200, 602-609 (2003
13. Evans, J.A. et al. Identifying intestinal metaplasia at the squamocolumnar junction by using optical coherence tomography. Gastrointest. Endosc. 65, 50-56 (2007
14. Qiu, L. et al. Multispectral scanning during endoscopy guides biopsy of dysplasia in Barrett's esophagus. Nat. Med. 16, 603-606 (2010
15. Waldner, M.J., Wirtz, S., Neufert, C., Becker, C. & Neurath, M.F. Confocal laser endomicroscopy and narrow-band imaging-Aided endoscopy for in vivo imaging of colitis and colon cancer in mice. Nat. Protoc. 6, 1471-1481 (2011
16. Kiesslich, R. et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 132, 874-882 (2007
17. Hsiung, P.L. et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat. Med. 14, 454-458 (2008
18. ten Hove, T., van Montfrans, C., Peppelenbosch, M.P. & van Deventer, S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50, 206-211 (2002
19. Atreya, R. et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14 macrophages. Gastroenterology 141, 2026-2038 (2011
20. Kaymakcalan, Z. et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin. Immunol. 131, 308-316 (2009
21. Kiesslich, R., Goetz, M., Vieth, M., Galle, P.R. & Neurath, M.F. Technology insight: Confocal laser endoscopy for in vivo diagnosis of colorectal cancer. Nat. Clin. Pract. Oncol. 4, 480-490 (2007
22. Neurath, M.F. & Travis, S.P. Mucosal healing in inflammatory bowel diseases: A systematic review. Gut 61, 1619-1635 (2012
23. Bird-Lieberman, E.L. et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat. Med. 18, 315-321 (2012
24. Medarova, Z., Rashkovetsky, L., Pantazopoulos, P. & Moore, A. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res. 69, 1182-1189 (2009
25. Monteleone, G., Pallone, F. & MacDonald, T.T. Emerging immunological targets in inflammatory bowel disease. Curr. Opin. Pharmacol. 11, 640-645 (2011
26. Kamada, N. et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-? axis. J. Clin. Invest. 118, 2269-2280 (2008
27. Van Den Brande, J.M. et al. Prediction of antitumour necrosis factor clinical efficacy by real-Time visualisation of apoptosis in patients with Crohn's disease. Gut 56, 509-517 (2007
28. Van Den Brande, J.M. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774-1785 (2003
29. Mitoma, H. et al. Infliximab induces potent anti-inflammatory responses by outside-To-inside signals through transmembrane TNF-A. Gastroenterology 128, 376-392 (2005
30. Reinisch, W. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 60, 780-787 (2011
31. Broadbridge, V.T., Karapetis, C.S. & Price, T.J. Cetuximab in metastatic colorectal cancer. Expert Rev. Anticancer Ther. 12, 555-565 (2012
32. Macedo, L.T., da Costa Lima, A.B. & Sasse, A.D. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: A systematic review and meta-Analysis, with emphasis on chemotherapy subgroups. BMC Cancer 12, 89 (2012
33. Foersch, S. et al. Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy. Gut 59, 1046-1055 (2010
34. Hueber, W. et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 (2010
35. Papp, K.A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181-1189 (2012
36. Leonardi, C. et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366, 1190-1199 (2012
37. Tanaka, T., Narazaki, M. & Kishimoto, T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 585, 3699-3709 (2011
38. Rubin, D.T., Panaccione, R., Chao, J. & Robinson, A.M. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr. Med. Res. Opin. 27, 1803-1813 (2011
39. Rutgeerts, P. et al. Adalimumab induces and maintains mucosal healing in patients with crohn's disease: Data from the EXTEND trial. Gastroenterology 142, 1102-1111. e1102 (2012
40. Riley, S.A. et al. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 29, 669-674 (1988